TABLE 5.
PSYCHOTROPIC AND COGNITIVE-ENHANCING MEDICATION USE AMONG STUDY PARTICIPANTS
| DSAL (n = 18) | TAL (n = 28) | |||||
|---|---|---|---|---|---|---|
| Medication Category/Agent | Total (N = 46) | Dementia Diagnosisa (n = 15) | No Dementia Diagnosisa (n = 3) | Dementia Diagnosisa (n = 9) | No Dementia Diagnosisa (n = 19) | p Value |
| n (%) | n (%) | n (%) | n (%) | n (%) | ||
| Antidepressant agents | 20 (44) | 8 (53) | 2 (67) | 3 (33) | 7 (37) | 0.23 |
| Selective serotonin reuptake inhibitors | [13] | [5] | [2] | [2] | [4] | |
| Mirtazapine (Remeron®) | [5] | [2] | [1] | [2] | ||
| Venlafaxine (Effexor®) | [2] | [1] | [0] | [1] | ||
| Antipsychotic agents | 12 (26) | 10 (67) | 1 (33) | 0 (0) | 1 (5) | <0.001 |
| Quetiapine (Seroquel®) | [7] | [6] | [1] | |||
| Risperidone (Risperdal®) | [3] | [2] | [1] | |||
| Haloperidol (Haldol®) | [2] | [2] | ||||
| Anxiolytic agents | 12 (26) | 9 (60) | 0 (0) | 0 (0) | 3 (16) | 0.02 |
| Lorazepam (Ativan®) | [6] | [6] | ||||
| Alprazolam (Xanax®) | [3] | [2] | [1] | |||
| Buspirone (Buspar®) | [2] | [1] | [1] | |||
| Clonazepam (Klonopin®) | [1] | [1] | ||||
| Mood-stabilizing agents | 3 (7) | 0 (0) | 1 (33) | 0 (0) | 2 (11) | 1.00 |
| Gabapentin (Neurontin®) | [3] | [1] | [2] | |||
| Cognitive-enhancing agents | 20 (44) | 13 (87) | 0 (0) | 7 (78) | 0 (0) | <0.001 |
| Donepezil (Aricept®) | [9] | [7] | [2] | |||
| Galantamine (Razadyne®) | [6] | [3] | [3] | |||
| Memantine (Namenda®) | [5] | [3] | [2] | |||
| Sedative/hypnotic agents | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1.00 |
| Temazepam (Restoril®) | [1] | [1] | ||||
Note. DSAL = dementia-specific assisted living settings; TAL = traditional assisted living settings.
% represents percentage of column totals taking the category of medication.
Numbers in brackets provide detail regarding the types of medications and are subsumed in the number of participants taking medications in that category.
a
Percentages were calculated from the total number of participants within that setting.